文献速递瓣膜病与结构性心脏病

心肌肌球蛋白结合蛋白C是主动脉瓣狭窄心肌损伤和纤维化的新标志物

Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis.
PubMed 文献 · Heart · 2017-12-01

该研究在主动脉瓣狭窄患者中评估血清cMyC与心脏结构及预后的关联。机制队列(n=161)显示cMyC与左心室质量、纤维化体积和细胞外容积相关,且在有晚期钆增强者中更高;预后队列(n=104)中cMyC升高与全因死亡风险增加相关。

要点

  • 血清cMyC与主动脉瓣狭窄患者的心肌肥厚和纤维化相关。
  • cMyC在有心肌纤维化(LGE)的患者中浓度更高。
  • cMyC升高与主动脉瓣狭窄患者全因死亡风险增加相关。

核心结论

  • 血清cMyC浓度与主动脉瓣狭窄患者的心肌肥厚、纤维化及死亡风险增加相关。

研究设计与样本

  • 机制队列:主动脉瓣狭窄患者161例和健康对照46例,均接受心脏磁共振检查。
  • 预后队列:主动脉瓣狭窄患者104例,随访中位时间11.3年。

主要发现

  • 在主动脉瓣狭窄患者中,cMyC浓度与左心室质量相关(校正β=11.0 g/m2每log单位cMyC增加,P<0.001)。
  • cMyC与纤维化体积相关(校正β=8.0 g,P<0.001),与细胞外容积相关(校正β=1.3%,P=0.01);在对照中无此关联。
  • 有晚期钆增强(提示心肌纤维化)者cMyC浓度更高(32(21-56)ng/L vs 无LGE者17(12-24)ng/L,P<0.001)。
  • cMyC与冠状动脉钙化评分无关。
  • 预后队列未校正Cox分析显示,log cMyC每增加1单位,全因死亡风险HR 1.49(95%CI 1.11-2.01,P=0.009)。

临床怎么用

  • cMyC可作为评估主动脉瓣狭窄患者心肌损伤和纤维化的血清标志物。
  • cMyC可能有助于监测主动脉瓣狭窄疾病进展,但临床效用尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiac myosin-binding protein C (cMyC) is an abundant sarcomeric protein and novel highly specific marker of myocardial injury. Myocyte death characterises the transition from hypertrophy to replacement myocardial fibrosis in advanced aortic stenosis. We hypothesised that serum cMyC concentrations would be associated with cardiac structure and outcomes in patients with aortic stenosis. METHODS: cMyC was measured in two cohorts in which serum had previously been prospectively collected: a mechanism cohort of patients with aortic stenosis (n=161) and healthy controls (n=46) who underwent cardiac MRI, and an outcome cohort with aortic stenosis (n=104) followed for a median of 11.3 years. RESULTS: In the mechanism cohort, cMyC concentration correlated with left ventricular mass (adjusted β=11.0 g/m2 per log unit increase in cMyC, P<0.001), fibrosis volume (adjusted β=8.0 g, P<0.001) and extracellular volume (adjusted β=1.3%, P=0.01) in patients with aortic stenosis but not in controls. In those with late gadolinium enhancement (LGE) indicative of myocardial fibrosis, cMyC concentrations were higher (32 (21-56) ng/L vs 17 (12-24) ng/L without LGE, P<0.001). cMyC was unrelated to coronary calcium scores. Unadjusted Cox proportional hazards analysis in the outcome cohort showed greater all-cause mortality (HR 1.49 per unit increase in log cMyC, 95% CI 1.11 to 2.01, P=0.009). CONCLUSIONS: Serum cMyC concentration is associated with myocardial hypertrophy, fibrosis and an increased risk of mortality in aortic stenosis. The quantification of serum sarcomeric protein concentrations provides objective measures of disease severity and their clinical utility to monitor the progression of aortic stenosis merits further study. CLINICAL TRIAL REGISTRATION: NCT1755936; Post-results.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Anand A, Chin C, Shah ASV, et al. Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis. Heart. 2017. PMID: 29196542. doi:10.1136/heartjnl-2017-312257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。